BMS Q2 Revenue Dips Amid Rising R&D Spend
Ticker: CELG-RI · Form: 10-Q · Filed: Jul 31, 2025 · CIK: 14272
| Field | Detail |
|---|---|
| Company | Bristol Myers Squibb Co (CELG-RI) |
| Form Type | 10-Q |
| Filed Date | Jul 31, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Pharmaceuticals, Biotech, R&D Spending, Revenue Decline, Drug Development, 10-Q Filing, Healthcare
Related Tickers: CELG-RI, PFE, MRK, JNJ
TL;DR
BMS is sacrificing short-term revenue for long-term pipeline strength, so buy the dip if you believe in their R&D bets.
AI Summary
Bristol Myers Squibb Co. reported total revenues of $11.45 billion for the three months ended June 30, 2025, a decrease from $11.70 billion in the same period of 2024. Net product sales for the quarter were $10.98 billion, down from $11.26 billion year-over-year. Alliance and other revenues also saw a decline, falling to $470 million from $440 million in the prior year's quarter. For the six months ended June 30, 2025, total revenues reached $22.80 billion, a slight decrease from $23.05 billion in the first half of 2024. Research and development expenses for the quarter increased to $2.65 billion from $2.50 billion in Q2 2024, reflecting continued investment in drug development. The company's strategic outlook emphasizes ongoing R&D, with drug development expenses rising to $2.15 billion for the quarter from $2.00 billion in Q2 2024. Risks include potential impacts from chargebacks and cash discounts, which amounted to $2.05 billion for the quarter, and Medicaid and Medicare rebates, totaling $1.50 billion, both of which affect net product sales.
Why It Matters
Bristol Myers Squibb's slight revenue dip, coupled with increased R&D, signals a strategic pivot towards future pipeline growth, potentially impacting short-term profitability but strengthening long-term competitive positioning against rivals like Pfizer and Merck. Investors should monitor the success of new drug launches to offset patent expirations and maintain market share. For employees, sustained R&D investment suggests job stability in research and development sectors. Customers may see new innovative treatments emerge, while the broader market will observe how BMS navigates a challenging pharmaceutical landscape with expiring patents and intense competition.
Risk Assessment
Risk Level: medium — The company faces medium risk due to declining net product sales, which fell from $11.26 billion in Q2 2024 to $10.98 billion in Q2 2025, and increasing R&D expenses, up from $2.50 billion to $2.65 billion in the same period. These trends indicate potential pressure on profitability if new products don't materialize quickly enough to offset revenue declines.
Analyst Insight
Investors should closely monitor Bristol Myers Squibb's upcoming clinical trial results and new drug approvals. Consider holding existing positions if you have a long-term outlook, but be cautious of further short-term revenue erosion.
Financial Highlights
- revenue
- $11.45B
- revenue Growth
- -2.1%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Net Product Sales | $10.98B | -2.5% |
| Alliance and Other Revenues | $0.47B | 6.8% |
Key Numbers
- $11.45B — Total Revenues (Decreased from $11.70B in Q2 2024 to $11.45B in Q2 2025.)
- $10.98B — Net Product Sales (Declined from $11.26B in Q2 2024 to $10.98B in Q2 2025.)
- $2.65B — R&D Expenses (Increased from $2.50B in Q2 2024 to $2.65B in Q2 2025, indicating higher investment.)
- $2.05B — Chargebacks and Cash Discounts (Impacted net product sales in Q2 2025.)
- $1.50B — Medicaid and Medicare Rebates (Affected net product sales in Q2 2025.)
Key Players & Entities
- BRISTOL MYERS SQUIBB CO (company) — filer of the 10-Q
- $11.45 billion (dollar_amount) — total revenues for Q2 2025
- $11.70 billion (dollar_amount) — total revenues for Q2 2024
- $10.98 billion (dollar_amount) — net product sales for Q2 2025
- $11.26 billion (dollar_amount) — net product sales for Q2 2024
- $470 million (dollar_amount) — alliance and other revenues for Q2 2025
- $440 million (dollar_amount) — alliance and other revenues for Q2 2024
- $2.65 billion (dollar_amount) — research and development expenses for Q2 2025
- $2.50 billion (dollar_amount) — research and development expenses for Q2 2024
- SEC (regulator) — recipient of the 10-Q filing
FAQ
What were Bristol Myers Squibb's total revenues for Q2 2025?
Bristol Myers Squibb's total revenues for the three months ended June 30, 2025, were $11.45 billion, a decrease from $11.70 billion in the same period of 2024.
How did Bristol Myers Squibb's net product sales change in Q2 2025?
Net product sales for Bristol Myers Squibb in Q2 2025 were $10.98 billion, down from $11.26 billion in the second quarter of 2024.
What was Bristol Myers Squibb's investment in research and development during Q2 2025?
Bristol Myers Squibb's research and development expenses increased to $2.65 billion in Q2 2025, up from $2.50 billion in Q2 2024.
What factors impacted Bristol Myers Squibb's net product sales in Q2 2025?
Net product sales were impacted by chargebacks and cash discounts of $2.05 billion and Medicaid and Medicare rebates totaling $1.50 billion in Q2 2025.
What is Bristol Myers Squibb's strategic outlook based on this 10-Q?
The strategic outlook for Bristol Myers Squibb emphasizes continued investment in R&D, with drug development expenses rising to $2.15 billion for Q2 2025, indicating a focus on future pipeline growth despite current revenue dips.
What are the key risks for Bristol Myers Squibb identified in the 10-Q?
Key risks for Bristol Myers Squibb include declining net product sales and the financial impact of significant chargebacks, cash discounts, and government rebates, which totaled $2.05 billion and $1.50 billion respectively in Q2 2025.
How might Bristol Myers Squibb's increased R&D spending affect investors?
Increased R&D spending by Bristol Myers Squibb, up to $2.65 billion in Q2 2025, could lead to short-term pressure on earnings but potentially drive long-term value through successful new drug development and approvals.
What were Bristol Myers Squibb's total revenues for the first half of 2025?
For the six months ended June 30, 2025, Bristol Myers Squibb's total revenues were $22.80 billion, a slight decrease from $23.05 billion in the first half of 2024.
Did Bristol Myers Squibb's alliance and other revenues change in Q2 2025?
Yes, Bristol Myers Squibb's alliance and other revenues for Q2 2025 were $470 million, a slight increase from $440 million in the same period of 2024.
What is the significance of the 10-Q filing date for Bristol Myers Squibb?
The 10-Q filing on July 31, 2025, provides a quarterly financial snapshot for Bristol Myers Squibb, covering the period ending June 30, 2025, and offering transparency on its financial performance and strategic direction to regulators and investors.
Risk Factors
- Chargebacks and Cash Discounts Impact [medium — financial]: Chargebacks and cash discounts amounted to $2.05 billion in Q2 2025, directly reducing net product sales. This represents a significant reduction in realized revenue from gross sales.
- Medicaid and Medicare Rebates Impact [medium — financial]: Medicaid and Medicare rebates totaled $1.50 billion in Q2 2025, further decreasing net product sales. These government rebates are a substantial factor affecting the company's top-line revenue recognition.
- Research and Development Investment [medium — operational]: R&D expenses increased to $2.65 billion in Q2 2025 from $2.50 billion in Q2 2024. While indicating investment in future growth, this also represents a significant ongoing cost.
Industry Context
The pharmaceutical industry is characterized by high R&D costs, patent cliffs, and significant regulatory oversight. Companies like Bristol Myers Squibb compete on innovation, drug pipeline strength, and market access. Trends include a focus on biologics, gene therapies, and personalized medicine, alongside increasing pricing pressures from payers.
Regulatory Implications
Bristol Myers Squibb operates in a highly regulated environment. Compliance with FDA regulations for drug approval and manufacturing, as well as pricing and rebate regulations for government programs like Medicare and Medicaid, are critical. Changes in healthcare policy can significantly impact revenue and profitability.
What Investors Should Do
- Monitor R&D pipeline progress
- Analyze impact of rebates and discounts
- Evaluate revenue diversification
Glossary
- Chargebacks and cash discounts
- Reductions from gross sales price due to agreements with third parties (like PBMs) or early payment incentives. (These directly reduce the net revenue recognized from product sales, impacting the top line.)
- Medicaid and Medicare rebates
- Discounts provided to government healthcare programs (Medicaid and Medicare) as required by law, reducing net sales. (A significant factor in the pharmaceutical industry that lowers the effective price of drugs sold to government entities.)
- Alliance and other revenues
- Revenue generated from partnerships, licensing agreements, and other sources outside of direct product sales. (Represents diversified revenue streams that can supplement core product sales.)
Year-Over-Year Comparison
Total revenues for the three months ended June 30, 2025, were $11.45 billion, a slight decrease from $11.70 billion in the same period of 2024. Net product sales also saw a decline, falling from $11.26 billion to $10.98 billion year-over-year. However, R&D expenses increased to $2.65 billion from $2.50 billion, indicating continued investment in future growth despite the revenue dip. New risks related to the magnitude of chargebacks, discounts, and government rebates impacting net sales are highlighted.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 31, 2025 regarding BRISTOL MYERS SQUIBB CO (CELG-RI).